The article presents experience and clinical and immunological effectiveness of
the use of recombinant interleukin-2 (rIL-2) in the treatment and prevention of
pneumonia in order to reduce the risk of pneumonia in cerebral strokes and
severe exogenous poisoning. Accumulated clinical experience on the use of
recombinant interleukin-2 in patients of various age groups indicates the
validity and feasibility of including the drug in the basic therapy for severe
pneumonia along with antimicrobial chemotherapy in order to normalize
immunological parameters, improve clinical course of the disease, achieve timely
and complete resolution of the inflammatory process.
